-
2型糖尿病(T2DM)是目前内分泌代谢领域的常见病。预计到2045年,超过7亿人可能患有糖尿病[1]。然而,探索其发病机制,并寻找有效的诊断及治疗方案,仍然是目前学术界的主要难题。Nesfatin-1是一种饱食分子,参与能量调节[2]。研究表明,Nesfatin-1除能抑制食欲外,还能改善外周组织胰岛素敏感性[3],增加胰岛素分泌[4-5]。减少白色脂肪分布[6-7],然而Nesfatin-1与T2DM的关系至今尚不明确。本研究旨在通过观察不同糖耐量状态的病人血清中Nesfatin-1的水平差异,初步探讨血清Nesfatin-1水平与T2DM之间的关联。为临床诊断提供更为早期的生物学指标,并为T2DM及其慢性并发症的治疗提供更好的靶点。
-
各组间的性别构成比差异无统计学意义(P>0.05),健康对照组和T2DM组年龄均大于PreDM组,差异均有统计学意义(P < 0.01)(见表 1)。
指标 健康对照组(n=52) PreDM组(n=60) T2DM组(n=60) F P MS组内 年龄/岁 59.32±10.95 50.63±11.61** 61.29±12.18△△ 14.14 < 0.01 135.033 男[n; 百分数(%)] 27(51.9) 31(51.7) 32(53.3) 0.38# >0.05 — WHR 0.77±0.38 0.83±0.59 0.91±0.52 1.07 >0.05 0.259 BMI/(kg/m2) 22.10±2.47 23.56±2.59** 25.41±3.27**△△ 19.52 < 0.01 7.916 FPG/(mmol/L) 4.90±0.61 6.08±0.66** 9.75±1.33**△△ 416.06 < 0.01 0.882 FIns(mIU/L) 4.67±1.20 6.03±1.89** 5.65±1.26** 12.07 < 0.01 2.236 HOMA-β/% 80.49±38.02 48.80±17.08** 18.85±5.60**△△ 96.46 < 0.01 549.016 HbA1c/% 5.14±0.74 6.86±2.20** 9.40±2.00**△△ 79.64 < 0.01 3.251 Nesfatin-1/(ng/mL) 1.26±0.46 1.60±0.63** 0.95±0.26**△△ 28.06 < 0.01 0.226 q检验:与健康对照组比较**P < 0.01;与PreDM组比较△△P < 0.01。#示χ2值 表 1 各指标在健康对照组、PreDM组及T2DM组中的比较
-
与健康对照组比较,PreDM组BMI、FPG、FIns、Nesfatin-1、HbA1c升高,HOMA-β下降,T2DM组BMI、FPG、FIns、HbA1c升高,HOMA-β、Nesfatin-1下降,差异均有统计学意义(P < 0.01);与PreDM组比较,T2DM组BMI、FPG、HbA1c升高,HOMA-β、Nesfatin-1、FIns下降,差异均有统计学意义(P < 0.01)(见表 1)。
-
所有受试者血清Nesfatin-1与WHR、BMI、FIns、HOMA-β呈正相关,与FPG呈负相关(P < 0.05~P < 0.01),与HbA1c无相关性(P>0.05)(见表 2)。
指标 WHR BMI FPG FIns HbA1c HOMA-β r 0.188 0.345 -0.218 0.489 0.082 0.163 P < 0.05 < 0.01 < 0.01 < 0.01 >0.05 < 0.05 表 2 Nesfatin-1与其余各指标的相关性分析
-
以FPG作为因变量,BMI、WHR、FIns、Nesfatin-1作为自变量进行多重线性回归分析,结果显示,FPG值随着BMI、WHR、FIns值升高而增高,随着Nesfatin-1值的升高而降低(P < 0.05~P < 0.01)(见表 3)。
变量 B SE B′ t P 常量 -11.036 1.026 — 10.75 < 0.01 WHR 20.184 1.539 0.694 13.12 < 0.01 BMI 0.106 0.041 0.145 2.61 < 0.05 FIns 0.186 0.073 0.130 2.54 < 0.05 Nesfatin_1 -1.930 0.201 -0.463 9.61 < 0.01 表 3 FPG与BMI、WHR、FIns、Nesfatin-1多重线性回归分析
Nesfatin-1在不同糖耐量病人血清中的水平差异分析
Variation analysis of the serum levels of Nesfatin-1 in patients with different glucose tolerance
-
摘要:
目的分析Nesfatin-1在不同糖耐量病人血清中的差异,探讨Nesfatin-1与2型糖尿病(T2DM)发生发展的关系。 方法选取糖尿病前期(PreDM)组包括空腹血糖受损(IFG)组及糖耐量异常(IGT)60例、T2DM组60例,另择同期体检健康者52名作为健康对照组,测定受试者体质量指数(BMI)、腰臀比(WHR)、空腹血糖(FPG)、空腹胰岛素(FIns)、糖化血红蛋白(HbA1c)、胰岛β细胞功能指数(HOMA-β)、Nesfatin-1。 结果与健康对照组比较,PreDM组BMI、FPG、FIns、Nesfatin-1、HbA1c升高,HOMA-β下降,T2DM组BMI、FPG、FIns、HbA1c升高,HOMA-β、Nesfatin-1下降,差异均有统计学意义(P < 0.01)。与PreDM组比较,T2DM组BMI、FPG、HbA1c升高,HOMA-β、Nesfatin-1、FIns下降,差异均有统计学意义(P < 0.01)。Nesfatin-1与WHR、BMI、FIns、HOMA-β呈正相关,与FPG呈负相关(P < 0.05~P < 0.01)。多重线性回归分析显示,FPG值随着BMI、WHR、FIns值升高而增高,随着Nesfatin-1值升高而降低(P < 0.05~P < 0.01)。 结论血清Nesfatin-1是影响糖代谢的因素之一。Nesfatin-1水平的下降很有可能参与了T2DM的发生发展。 -
关键词:
- 糖尿病, 2型 /
- 糖尿病前期 /
- Nesfatin-1 /
- 糖耐量
Abstract:ObjectiveTo analyze the difference of the serum levels of Nesfatin-1 in patients with different glucose tolerance, and explore the relationship between Nesfatin-1 level and occurrence, development of type 2 diabetes mellitus(T2DM). MethodsSixty pateints with impaired fasting glucose(IFG) and impaired glucose tolerance(IGT), 60 patients with T2DM and 52 health examinees at the same time were divided into the prediabetes group(PreDM), T2DM group and healthy control group, respectively.The body mass index(BMI), waist hip ratio(WHR), fasting plasma glucose(FPG), fasting insulin(FIns), glycosylated hemoglobin(HbA1c), islet β-cell function index(HOMA-β) and Nesfatin-1 were detected in three groups. ResultsCompared with the healthy control group, the BMI, FPG, FIns, Nesfatin-1 and HbA1c increased significantly, the HOMA-β decreased significantly in PreDM group, and the differences of which were statistically significant between two groups(P < 0.01).Compared with the healthy control group, the BMI, FPG, FIns and HbA1c increased significantly, and the HOMA-β and the Nesfatin-1 decreased significantly in T2DM group, and the differences of which were statistically significant between two groups(P < 0.01).Compared with the PreDM group, the BMI, FPG and HbA1c increased significantly, the HOMA-β, Nesfatin-1 and FIns decreased significantly in T2DM group, and the differences of which were statistically significant between two groups(P < 0.01).The Nesfatin-1 was positively correlated with the WHR, BMI, FIns and HOMA-β, and negatively correlated with the FPG(P < 0.05 to P < 0.01).The results of multiple linear regression analysis showed that the FPG increased with the increasing of BMI, WHR and FIns, and decreased with the increasing of Nesfatin-1(P < 0.05 to P < 0.01). ConclusionsThe serum Nesfatin-1 is one of the factors affecting glucose metabolism.The decrease of Nesfatin-1 level is likely to be involved in the occurrence and development of T2DM. -
Key words:
- diabetes mellitus, type 2 /
- prediabetes /
- Nesfatin-1 /
- glucose tolerance
-
表 1 各指标在健康对照组、PreDM组及T2DM组中的比较
指标 健康对照组(n=52) PreDM组(n=60) T2DM组(n=60) F P MS组内 年龄/岁 59.32±10.95 50.63±11.61** 61.29±12.18△△ 14.14 < 0.01 135.033 男[n; 百分数(%)] 27(51.9) 31(51.7) 32(53.3) 0.38# >0.05 — WHR 0.77±0.38 0.83±0.59 0.91±0.52 1.07 >0.05 0.259 BMI/(kg/m2) 22.10±2.47 23.56±2.59** 25.41±3.27**△△ 19.52 < 0.01 7.916 FPG/(mmol/L) 4.90±0.61 6.08±0.66** 9.75±1.33**△△ 416.06 < 0.01 0.882 FIns(mIU/L) 4.67±1.20 6.03±1.89** 5.65±1.26** 12.07 < 0.01 2.236 HOMA-β/% 80.49±38.02 48.80±17.08** 18.85±5.60**△△ 96.46 < 0.01 549.016 HbA1c/% 5.14±0.74 6.86±2.20** 9.40±2.00**△△ 79.64 < 0.01 3.251 Nesfatin-1/(ng/mL) 1.26±0.46 1.60±0.63** 0.95±0.26**△△ 28.06 < 0.01 0.226 q检验:与健康对照组比较**P < 0.01;与PreDM组比较△△P < 0.01。#示χ2值 表 2 Nesfatin-1与其余各指标的相关性分析
指标 WHR BMI FPG FIns HbA1c HOMA-β r 0.188 0.345 -0.218 0.489 0.082 0.163 P < 0.05 < 0.01 < 0.01 < 0.01 >0.05 < 0.05 表 3 FPG与BMI、WHR、FIns、Nesfatin-1多重线性回归分析
变量 B SE B′ t P 常量 -11.036 1.026 — 10.75 < 0.01 WHR 20.184 1.539 0.694 13.12 < 0.01 BMI 0.106 0.041 0.145 2.61 < 0.05 FIns 0.186 0.073 0.130 2.54 < 0.05 Nesfatin_1 -1.930 0.201 -0.463 9.61 < 0.01 -
[1] SAEEDI P, PETERSOHN I, SALPEA P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Res Clin Pract, 2019, 157: 107843. doi: 10.1016/j.diabres.2019.107843 [2] PSILOPANAGIOTI A, NIKOU S, PAPADAKI H. Nucleobindin-2/nesfatin-1 in the human hypothalamus is reduced in obese subjects and colocalizes with oxytocin, vasopressin, melanin-concentrating hormone, and cocaine- and amphetamine-regulated transcript[J]. Neuroendocrinology, 2019, 108(3): 190. doi: 10.1159/000496731 [3] DORE R, LEVATA L, LEHNERT H, et al. Nesfatin-1: functions and physiology of a novel regulatory peptide[J]. J Endocrinol, 2017, 232(1): R45. doi: 10.1530/JOE-16-0361 [4] NAKATA M, MANAKA K, YAMAMOTO S, et al. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca2+ influx through L-type channels in mouse islet β-cells[J]. Endocr J, 2011, 58(4): 305. doi: 10.1507/endocrj.K11E-056 [5] YANG Y, ZHANG B, NAKATA M, et al. Islet β-cell-produced NUCB2/nesfatin-1 maintains insulin secretion and glycemia along with suppressing UCP-2 in β-cells[J]. J Physiol Sci, 2019, 69(5): 733. doi: 10.1007/s12576-019-00689-2 [6] AYADA C, TORU V, KORKUT Y. Nesfatin-1 and its effects on different systems[J]. Hippokratia, 2015, 19(1): 4. [7] NAKATA M, YADA T. Role of NUCB2/nesfatin-1 in glucose control: diverse functions in islets, adipocytes and brain[J]. Curr Pharm Des, 2013, 19(39): 6960. doi: 10.2174/138161281939131127130112 [8] WU T, QIAO S, SHI C, et al. The metabolomics window into diabetic complications[J]. J Diabetes Investig, 2018, 9(2): 244. doi: 10.1111/jdi.12723 [9] IGELL I, SAUNDERS KH, FINS JJ. Why weight? An analytic review of obesity management, diabetes prevention, and cardiovascular risk reduction[J]. Curr Atheroscler Rep, 2018, 20(8): 39. doi: 10.1007/s11883-018-0740-z [10] OH-I S, SHIMIZU H, SATOH T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus[J]. Nature, 2006, 443(7112): 709. doi: 10.1038/nature05162 [11] TACHÉ Y, STENGEL A. New developments on NUCB2/nesfatin-1[J]. Curr Pharm Des, 2013, 19(39): 6919. doi: 10.2174/138161281939131127122941 [12] SCHALLA MA, STENGEL A. Current understanding of the role of Nesfatin-1[J]. J Endocr Soc, 2018, 2(10): 1188. doi: 10.1210/js.2018-00246 [13] YANG M, ZHANG Z, WANG C, et al. Nesfatin-1 action in the brain increases insulin sensitivity through Akt/AMPK/TORC2 pathway in diet-induced insulin resistance[J]. Diabetes, 2012, 61(8): 1959. doi: 10.2337/db11-1755 [14] LI Z, GAO L, TANG H, et al. Peripheral effects of nesfatin-1 on glucose homeostasis[J]. PLoS One, 2013, 8(8): e71513. doi: 10.1371/journal.pone.0071513 [15] LIU F, YANG Q, GAO N, et al. Decreased plasma nesfatin-1 level is related to the thyroid dysfunction in patients with type 2 diabetes mellitus[J]. J Diabetes Res, 2014, 2014: 128014. [16] ZHANG Z, LI L, YANG M, et al. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus[J]. Exp Clin Endocrinol Diabetes, 2012, 120(2): 91. doi: 10.1055/s-0031-1286339 [17] RIVA M, NITERT M D, VOSS U, et al. Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects[J]. Cell Tissue Res, 2011, 346: 393. doi: 10.1007/s00441-011-1268-5 [18] CHEN K, ZHUO T, WANG J, et al. Saxagliptin upregulates Nesfatin-1 secretion and ameliorates insulin resistance and metabolic profiles in type 2 diabetes mellitus[J]. Metab Syndr Relat Disord, 2018, 16(7): 336. doi: 10.1089/met.2018.0010